Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Plasma Cell Leukemia Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space – AbbVie, Bristol-Myers Squibb, Chimerix, Amgen, Celgene, Genentech

Published

on

<!– Name:DistributionId Value:8831879 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:e63be1b0-ac23-4544-b15a-acdca021d98f –>

New York, USA, May 11, 2023 (GLOBE NEWSWIRE) — Plasma Cell Leukemia Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space – AbbVie, Bristol-Myers Squibb, Chimerix, Amgen, Celgene, Genentech

The dynamics of the plasma cell leukemia market are anticipated to change in the coming years owing to the improvement in the research and development undertaking. In addition, the anticipated launch of emerging therapies and an increase in incidence will also fuel the plasma cell leukemia market size in the 7MM in the coming years.

DelveInsight’s Plasma Cell Leukemia Market Insights report includes a comprehensive understanding of current treatment practices, plasma cell leukemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Plasma Cell Leukemia Market Report

  • As per DelveInsight analysis, the plasma cell leukemia market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • As per the data published in Blood Cancer Journal (2021), 60–70% of cases have been reported to be primary plasma cell leukemia (pPCL), whereas ~40% are secondary. In recent years, there has been an increase in the incidence of secondary plasma cell leukemia, likely related to more effective therapies contributing to both improved survival and clonal selection over time.
  • Leading plasma cell leukemia companies such as Denovo Biopharma, Orbus Therapeutics, Onconeutics, Celgene, Oblato, AbbVie, Genentech, Atara Bio, Bristol-Myers Squibb, Chimerix, Rapa Therapeutics LLC, GPCR Therapeutics, Inc., Amgen, Sorrento Therapeutics, Inc., Cartesian Therapeutics, Virtuoso BINco, Inc., Gadeta B.V., Inc., and others are developing novel plasma cell leukemia drugs that can be available in the plasma cell leukemia market in the coming years.
  • Some of the key therapies for plasma cell leukemia treatment include Venetoclax, WT1 sensitized T cells, Nivolumab, Lenalidomide, ONC201, RAPA-201 Autologous T cells, GPC-100, Denosumab, STI-6129, Descartes 08, VP301, TEG002, and others.
  • Several plasma cell leukemia therapies are in various stages of development, and their anticipated launch will drive the plasma cell leukemia market forward. 

Discover which therapies are expected to grab the major plasma cell leukemia market share @ Plasma Cell Leukemia Market Report

Plasma Cell Leukemia Overview

Plasma cell leukemia is a form of multiple myeloma. It is an aggressive cancer that arises in the bone marrow plasma. It is a rare kind of multiple myeloma. There are two forms of plasma cell leukemia: the first is primary plasma cell leukemia, which is cancer that originates in its original form rather than spreading to the blood from another type of cancer. Primary plasma cell leukemia is genetically separate from multiple myeloma. The second type is secondary plasma cell leukemia, which occurs when multiple myeloma changes and spreads to the blood.

The primary causes of plasma cell leukemia are unknown. Genetic abnormalities in plasma cell development may cause plasma cell leukemia. Exposure to environmental pollutants such as pollution and the cell-damaging effects of age may result in this type of cancer. Blood tests, biopsies, immunoglobulin-free light chain tests, and imaging scans such as CT or MRI are all used for plasma cell leukemia diagnosis. 

Plasma Cell Leukemia Epidemiology Segmentation

The plasma cell leukemia epidemiology section provides insights into the historical and current plasma cell leukemia patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The plasma cell leukemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Plasma Cell Leukemia Incident Cases
  • Plasma Cell Leukemia Type-Specific Cases
  • Plasma Cell Leukemia Treatable Cases 

Download the report to understand which factors are driving plasma cell leukemia epidemiology trends @ Plasma Cell Leukemia Epidemiological Insights

Plasma Cell Leukemia Treatment Market 

Plasma cell leukemia treatment aims to reduce the number of plasma cells in the blood and bone marrow, preferably reaching complete remission. Because plasma cell leukemia is so aggressive, therapy must begin as soon as possible. The first stage of plasma cell leukemia treatment is known as induction. The purpose of induction is to help diminish the number of cancer cells in the body. Bortezomib (Velcade), a targeted therapy medication, is frequently used during induction. It may also be used as part of combination therapy with the immunomodulator lenalidomide (Revlimid) and the steroid dexamethasone.

Typically, autologous stem cell transplants are employed. Prior to the transplant, healthy stem cells are extracted from the patient’s body rather than from a donor. A large dose of chemotherapy is given prior to a stem cell transplant to kill the cells in the bone marrow. This kills both normal and malignant cells. The previously obtained stem cells are then infused. The goal is for these cells to colonize the body and establish healthy bone marrow. A simultaneous stem cell transplant may also be advised. This entails receiving two autologous stem cell transplants in quick succession. Receiving a tandem stem cell transplant may aid in overall survival.

Following a stem cell transplant, maintenance therapy is administered. After induction therapy, a person who is eligible for a stem cell transplant may get maintenance therapy. Maintenance therapy aims to help prevent cancer from relapsing or returning. Bortezomib, lenalidomide, or both are frequently used.

To know more about plasma cell leukemia treatment, visit @ Plasma Cell Leukemia Treatment Drugs 

Key Plasma Cell Leukemia Therapies and Companies

  • Venetoclax: AbbVie/Genentech
  • WT1 sensitized T cells: Atara Bio
  • Nivolumab: Bristol-Myers Squibb
  • Lenalidomide: Celgene
  • ONC201: Chimerix
  • RAPA-201 Autologous T cells: Rapa Therapeutics LLC
  • GPC-100: GPCR Therapeutics, Inc.
  • Denosumab: Amgen
  • STI-6129: Sorrento Therapeutics, Inc.
  • Descartes 08: Cartesian Therapeutics
  • VP301: Virtuoso BINco, Inc.
  • TEG002: Gadeta B.V.

Learn more about the FDA-approved drugs for plasma cell leukemia @ Drugs for Plasma Cell Leukemia Treatment 

Plasma Cell Leukemia Market Dynamics

The plasma cell leukemia market is expected to change in the coming years. Increasing research and development to comprehend the disease’s diversity may enhance the diagnosis of plasma cell leukemia, leading to a potential plasma cell leukemia market opportunity. Current treatments are utilized to alleviate symptoms and improve patients’ quality of life. Moreover, several organizations are currently striving to provide information and raise awareness about such conditions. There are fewer therapy choices for plasma cell leukemia, which opens the door for novel medicines to enter the plasma cell leukemia market. The expected introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are likely to boost the growth of the plasma cell leukemia market in the 7MM.

However, certain factors may affect the growth of the plasma cell leukemia market. Plasma cell leukemia is a rare neoplasm of plasma cells with an aggressive clinical course and poor outcome, even with the current standard of care. There are no particular therapeutic response criteria for plasma cell leukemia treatment. Furthermore, the plasma cell leukemia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the plasma cell leukemia market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Plasma Cell Leukemia Companies Denovo Biopharma, Orbus Therapeutics, Onconeutics, Celgene, Oblato, AbbVie, Genentech, Atara Bio, Bristol-Myers Squibb, Chimerix, Rapa Therapeutics LLC, GPCR Therapeutics, Inc., Amgen, Sorrento Therapeutics, Inc., Cartesian Therapeutics, Virtuoso BINco, Inc., Gadeta B.V., and others
Key Plasma Cell Leukemia Therapies Venetoclax, WT1 sensitized T cells, Nivolumab, Lenalidomide, ONC201, RAPA-201 Autologous T cells, GPC-100, Denosumab, STI-6129, Descartes 08, VP301, TEG002, and others

Scope of the Plasma Cell Leukemia Market Report

  • Therapeutic Assessment: Plasma Cell Leukemia current marketed and emerging therapies
  • Plasma Cell Leukemia Market Dynamics: Attribute Analysis of Emerging Plasma Cell Leukemia Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Plasma Cell Leukemia Market Access and Reimbursement

Discover more about plasma cell leukemia drugs in development @ Plasma Cell Leukemia Clinical Trials

Table of Contents

1. Plasma Cell Leukemia Market Key Insights
2. Plasma Cell Leukemia Market Report Introduction
3. Plasma Cell Leukemia Market Overview at a Glance
4. Plasma Cell Leukemia Market Executive Summary
5. Disease Background and Overview
6. Plasma Cell Leukemia Treatment and Management
7. Plasma Cell Leukemia Epidemiology and Patient Population
8. Patient Journey
9. Plasma Cell Leukemia Marketed Drugs
10. Plasma Cell Leukemia Emerging Drugs
11. Seven Major Plasma Cell Leukemia Market Analysis
12. Plasma Cell Leukemia Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Plasma Cell Leukemia Epidemiology Forecast

Plasma Cell Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted plasma cell leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple Myeloma Market

Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Multiple Myeloma Pipeline

Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.

Relapsing Refractory Multiple Myeloma Pipeline

Relapsing Refractory Multiple Myeloma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Refractory Multiple Myeloma Market

Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.

Relapsing Refractory Multiple Myeloma Market

Relapsing Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Plasma Cell Leukemia Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Blogs 

Multiple Myeloma Treatment Market 

Upcoming Oncology Drugs

Oncology Market Outlook

Future of Oncology Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Permira to Acquire Majority Position in BioCatch at $1.3bn Valuation

Published

on

permira-to-acquire-majority-position-in-biocatch-at-$1.3bn-valuation

Permira Growth Opportunities Transaction builds on initial minority investment made in early 2023 to acquire a majority position and support BioCatch’s accelerated growth within online fraud detection and financial crime prevention
NEW YORK and TEL AVIV, Israel, May 2, 2024 /PRNewswire/ — BioCatch (the “Company”), the global leader in digital fraud detection and financial crime prevention powered by behavioral biometric intelligence, today announced that Permira Growth Opportunities II (the “Fund”), a fund advised by global private equity firm Permira, has agreed to acquire a majority position in the Company. Alongside the Fund’s investment, existing shareholders Sapphire Ventures and Macquarie Capital will also increase their investments in BioCatch. The transaction is expected to accelerate the Company’s global expansion, advance its innovative product roadmap and support its continued overall growth.

Under the terms of the agreement, the Fund will acquire a majority stake in BioCatch, buying out shares primarily from Bain Capital Tech Opportunities and Maverick Ventures, in a secondary transaction valuing the Company at a total enterprise valuation of $1.3bn.
BioCatch was founded in 2011 – at the dawn of a significant consumer shift from branch to online banking – with a mission to fight fraud and keep users safe in online transactions without disrupting user experience. Today, the Company is a leader in behavioral biometric intelligence and advanced fraud detection, leveraging patented artificial intelligence, data science, and machine learning technology to analyze a user’s cognitive intent and deliver highly accurate insights as to the legitimacy of their identity, motivations, and behavior. In 2023, the Company expanded its mission to include a proactive approach to fighting financial crime with the launch of predictive, behavior-based mule account detection.
As fraud attacks have become increasingly scaled, sophisticated and complex, BioCatch has experienced significant and sustained momentum. Permira, via its growth equity strategy, completed an initial minority investment in the Company in early 2023, a year that BioCatch ultimately finished with 49% ARR growth, whilst also surpassing the $100 million ARR milestone and attaining EBITDA profitability. Today, BioCatch counts more than 190 financial institutions as customers globally, including over 30 of the world’s largest 100 global banks, who use its solutions to fight fraud, facilitate financial crime prevention and decision intelligence sharing, accelerate digital transformation, and grow the value of customer relationships.
Permira brings a growth mindset to BioCatch’s next chapter, with the ability and network to help the Company expand across Continental Europe, where Permira was first established nearly four decades ago. In addition, Permira is excited to back the Company’s exceptional management team and innovative product roadmap, and is committed to further strengthening BioCatch’s global leadership position both organically and inorganically.
“Permira has backed the theme of cybersecurity for several years, and within this, online fraud detection, customer identity and access management markets have become a clear focus. We have tracked BioCatch with enthusiasm for many years, and now having been a shareholder since early 2023, our conviction in the business, its growth potential, its technology leadership, and its management team continues to grow. We’re excited to become the company’s majority shareholder and look forward to a continued successful partnership with Gadi and the BioCatch team as we seek to further accelerate growth and expansion in the years to come,” said Stefan Dziarski, Partner and Co-Head of Permira Growth Opportunities.
Gadi Mazor, CEO of BioCatch, added: “After building a strong partnership with Permira over the last year, we are delighted to welcome them as majority shareholders. The firm’s impressive experience within technology and cybersecurity, combined with their scale, global network, and our close working relationship, has been invaluable since their initial investment. We’re excited to take BioCatch to the next level together. I’d also like to thank Matthew Kinsella from Maverick Ventures and Dewey Awad from Bain Capital for their support over the last four years, which has been key in helping us establish our leadership position in the market.”
“We have had the privilege of partnering with BioCatch over the past four years and worked closely with Gadi and the BioCatch team to develop a long-term strategy to realize the business’s growth potential,” said Dewey Awad, a Partner at Bain Capital. “Together, we drove several key initiatives aimed at augmenting BioCatch’s go-to-market strategy, team, and operations, all with the goal of protecting end-users and their most sensitive transactions. We believe the company is well-positioned to continue its growth journey under Gadi’s leadership and with Permira’s support.”
“At Permira, we are looking to back product-led businesses operating in structurally growing end markets and that have management teams with the ambition to scale and grow their business. We found all of that in BioCatch and were grateful to have the opportunity to make an initial investment in 2023. After a successful first year, we are delighted to take a majority stake in the business as it continues to grow at scale. With the full extent of Permira’s resources and experience at its disposal, we’re excited for what’s to come at BioCatch,” commented Ran Maidan, Senior Adviser and Head of Permira in Israel.
About Permira
Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of approximately €80bn and makes long-term majority and minority investments across two core asset classes, private equity and credit.
The Permira funds have an extensive track record in technology investing, having invested in 50+ companies across SaaS, cybersecurity, digital commerce, fintech and online marketplaces. Permira invested in BioCatch via its Growth Opportunities Fund; its strategy is to back disruptive technology and tech-enabled companies as they scale to the next level. The Permira funds have previously supported and helped scale some of the largest and fastest-growing technology businesses globally, including Genesys, TeamViewer, Zendesk, McAfee, Mimecast, Carta, G2, Sysdig, SonarSource, Mirakl, and others. Permira closed its second Growth Opportunities Fund in December 2021 at $4 billion.
The Permira private equity funds have made approximately 300 private equity investments in four key sectors: Technology, Consumer, Healthcare and Services. Permira employs over 500 people in 15 offices across Europe, the United States and Asia. For more information, visit www.permira.com or follow us on LinkedIn.
About BioCatch
BioCatch stands at the forefront of digital fraud detection, pioneering behavioral biometric intelligence grounded in advanced cognitive science and machine learning. BioCatch analyzes thousands of user interactions to support a digital banking environment where identity, trust, and ease coexist. Today, more than 30 of the world’s largest 100 banks and more than 190 total financial institutions rely on BioCatch Connect™ to combat fraud, facilitate digital transformation, and grow customer relationships.
BioCatch’s Client Innovation Board, an industry-led initiative featuring American Express, Barclays, Citi Ventures, HSBC, and National Australia Bank, collaborates to pioneer creative and innovative ways to leverage customer relationships for fraud prevention. With more than a decade of data analysis, 90 registered patents, and unmatched expertise, BioCatch continues to lead innovation to address future challenges. For more information, visit www.biocatch.com.
Media Contacts
For BioCatch
Mac KingSr. Manager, Corporate Communications, [email protected]+1-206-200-8596
For Permira
James [email protected] +44 774 7006407
Logo – https://mma.prnewswire.com/media/1843699/biocatch_logo_rgb_2x_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/permira-to-acquire-majority-position-in-biocatch-at-1-3bn-valuation-302133942.html

Continue Reading

Artificial Intelligence

JupiterOne and watchTowr announce partnership to protect business critical assets with broad exposure management capabilities

Published

on

jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities

SINGAPORE, May 2, 2024 /PRNewswire/ — watchTowr, a leader in external attack surface management (EASM) technology and fuelled by watchTowr Labs, a renowned vulnerability R&D capability, has formed a strategic partnership with JupiterOne. JupiterOne is a leader in cyber asset attack surface management (CAASM) technology. This collaboration enables customers to rapidly prioritize emerging threats within their constantly changing environments, focusing on fixing the most critical risks impacting their business, which enables an end-to-end continuous threat exposure management process (CTEM).

Over 28,000 CVE records were published in 2023; a figure that is expected to increase as attackers shorten the time from known vulnerability to exploit, reducing it from weeks to days. JupiterOne and watchTowr’s integrated solution empowers enterprises to discover their most critical and exploitable vulnerabilities, prioritize them with asset context based on business impact and receive an actionable remediation plan to improve security posture.
This partnership enables a complete continuous threat exposure management program, addressing the full spectrum of cyber risk management. The fully integrated solution provides continuous monitoring and assessment of both internal and external digital assets, allowing for prioritization and effective threat mitigation for a business’s most critical assets. “Our partnership with watchTowr is a game-changer” said Forte. “Combining our data aggregation with real-time asset discovery and automated security testing allows us to offer a unique, all-encompassing approach to exposure management.”
Benjamin Harris, CEO, watchTowr, said, “While the number of reported vulnerabilities continues to rise, the vulnerabilities that matter – in mission-critical, key systems – have exploded at an alarming rate. This reality, combined with the significant shift in speed by attackers to weaponize vulnerabilities – the ability to validate exploitability and prioritise actions based on real business risk has never been more vital. We’re excited to join forces with JupiterOne to give security teams around the globe this much-needed end-to-end capability.”
About JupiterOne:
JupiterOne is a cybersecurity startup delivering powerful software solutions to companies across all industries, providing deep insights to cyber assets and the relationships between, empowering security professionals to have true knowledge and ownership of their attack surfaces.
About watchTowr: 
watchTowr is a global cybersecurity technology company, built by former adversaries.
watchTowr’s world-class External Attack Surface Management and Continuous Automated Red Teaming technology is informed by years of experience compromising some of the world’s most targeted organisations and utilised by Fortune 500, financial services and critical infrastructure providers every day.
Photo – https://mma.prnewswire.com/media/2401497/watchTowr_JupiterOne.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jupiterone-and-watchtowr-announce-partnership-to-protect-business-critical-assets-with-broad-exposure-management-capabilities-302132392.html

Continue Reading

Artificial Intelligence

Clarivate Declares Dividend on Mandatory Convertible Preferred Shares

Published

on

clarivate-declares-dividend-on-mandatory-convertible-preferred-shares

LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.

On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html

Continue Reading

Trending